| Caitlin Rooney, DO | |
|
201 Nw Rd Mize Road, Blue Springs, MO 64014 | |
| (816) 655-5426 | |
| (816) 655-5408 |
| Full Name | Caitlin Rooney |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 11 Years |
| Location | 201 Nw Rd Mize Road, Blue Springs, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881000529 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 2014022225 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Belton Regional Medical Center | Belton, MO | Hospital |
| Menorah Medical Center | Overland park, KS | Hospital |
| Lee's Summit Medical Center | Lees summit, MO | Hospital |
| Research Medical Center | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas City Vascular And General Surgery Group Llc | 8224168927 | 21 |
| Kansas City Vascular And General Surgery Group Llc | 8224168927 | 21 |
News Archive
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
The University of British Columbia public affairs office has published today a story on probiotic intervention as the next potential weapon against malnutrition.
› Verified 9 days ago
| Entity Name | Kansas City Vascular & General Surgery Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295968865 PECOS PAC ID: 8224168927 Enrollment ID: O20100607000801 |
News Archive
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
The University of British Columbia public affairs office has published today a story on probiotic intervention as the next potential weapon against malnutrition.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Rooney, DO 201 Nw Rd Mize Road, Blue Springs, MO 64014 Ph: (816) 655-5426 | Caitlin Rooney, DO 201 Nw Rd Mize Road, Blue Springs, MO 64014 Ph: (816) 655-5426 |
News Archive
Flexible Stenting Solutions, a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption approval for its FlexStent Femoropopliteal Self Expanding Stent System.
Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
The University of British Columbia public affairs office has published today a story on probiotic intervention as the next potential weapon against malnutrition.
› Verified 9 days ago
Dr. Christine W Ku, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-655-5426 | |
Matthew Hentges, DO Surgery Medicare: Not Enrolled in Medicare Practice Location: 201 Nw R D Mize Rd Ste 210, Blue Springs, MO 64014 Phone: 816-655-5403 | |
Dr. Benjamin Kinderknecht, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
Luke Clippard, DO Surgery Medicare: Not Enrolled in Medicare Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-655-5361 Fax: 816-655-5408 | |
Dr. Jacob Wiepen, DO Surgery Medicare: Not Enrolled in Medicare Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-228-5900 |